Molecure SA
WSE:MOC
Net Margin
Molecure SA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| PL |
M
|
Molecure SA
WSE:MOC
|
121.2m PLN |
-1 439%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
729.6B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
372.9B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.2T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
213.3B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
190.2B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
167.2B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
198.7B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
132.7B USD |
13%
|
Molecure SA
Glance View
Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Molecure SA's most recent financial statements, the company has Net Margin of -1 438.9%.
You don't have any saved screeners yet